35Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  HS135 / 35Pharma
    HS135, a Novel Activin and GDF Trap, Is Efficacious in Models of Pulmonary Hypertension (PH) and Heart Failure (HF) (Walter E. Washington Convention Center, Area B, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_5746;    
    The best-in-class target engagement profile of HS135 translates into increased and differentiated efficacy improving the PH and HF phenotype in preclinical models. Collectively, these data support the development of HS135 as a novel agent in cardiometabolic and cardiopulmonary diseases including PAH and PH-associated with left heart disease.